Cyrus Harmon - 23 Jul 2026 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: Director
Issuer ticker: OLMA
Reported as of: 23 Jul 2026
Net transaction value: -$291,162
SEC form: 4
Accepted by SEC: 27 Jul 2026, 19:30:05 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawnte Mitchell, Attorney-in-Fact

Key filing fact

Cyrus Harmon filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 27 Jul 2026.

Key facts

This page summarizes Cyrus Harmon's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Jul 2026, 19:30.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$291,162.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001831410 Primary reporting owner

Harmon Cyrus

Relationship: Director
Address: C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO
Signature: /s/ Shawnte Mitchell, Attorney-in-Fact
Signature date: 27 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OLMA transaction

Common Stock

Sale

Transaction value: $144,738
Shares: -12,500
Change %: -1.7%
Price: $11.58
Shares after: 715,270
Date: 23 Jul 2026
Ownership: Direct
Footnotes: F1

OLMA transaction

Common Stock

Sale

Transaction value: $146,425
Shares: -12,500
Change %: -1.7%
Price: $11.71
Shares after: 702,770
Date: 24 Jul 2026
Ownership: Direct
Footnotes: F2

OLMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 117,028
Date: 23 Jul 2026
Ownership: See Footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F2

The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.